The U.S. Food and Drug Administration has approved the use of oral teriflunomide (Aubagio) 7 or 14 mg/day for the treatment of relapsing forms of MS. The drug was submitted for FDA review in October 2011. The drug has not yet been approved by Health Canada.
Latest News
Small, short-term benefit with physiotherapy in PD: meta-analysis
October 24, 2012A Cochrane meta-analysis has examined 33 trials (n=1,518) to determine the benefits of physiotherapy versus no physiotherapy in patients with Parkinson’s disease (Tomlinson et al. Cochrane Database Syst Rev 2012 Aug 15;8:CD002817). Interventions included general physiotherapy, exercise, treadmill training, dance and martial arts.
BG-12: Updated data from phase III studies
August 29, 2012REPORT FROM THE AMERICAN ACADEMY OF NEUROLOGY (AAN) ANNUAL MEETING, NEW ORLEANS LA, APRIL 21-28, 2012 – The efficacy and safety of the oral fumarate BG-12 has been evaluated in the phase III studies DEFINE and CONFIRM (see BG-12 in RRMS: DEFINE trial, NeuroSens, October 21, 2011; CONFIRM – Second phase III trial results for BG-12, NeuroSens, November 30, 2011). New data from both trials were presented at AAN.
Clobazam in Lennox-Gastaut syndrome: phase III results
August 29, 2012REPORT FROM THE AMERICAN ACADEMY OF NEUROLOGY (AAN) ANNUAL MEETING, NEW ORLEANS LA, APRIL 21-28, 2012 – The CONTAIN phase III trial evaluated the benzodiazepine derivative clobazam in patients with Lennox-Gastaut syndrome (LGS) (Ng et al. Neurology 2011;77:1473-1481). A total of 238 patients aged 2-60 years (mean 12.4 years) were randomized to one of three doses of clobazam (0.25, 0.5, 1.0 mg/kg/day) or placebo.
The trial consisted of a three-week titration phase and a 12-week maintenance phase. The average weekly seizure rate declined 41.2%, 49.4% and 68.3% with the three clobazam doses versus 12.1% with placebo (modified ITT analysis). Responder rates were 43.4%, 58.6% and 77.6% with clobazam versus 31.6% with placebo.